Sector News

Germany’s Merck KGaA sees emerging markets as bigger earnings driver than Europe

March 30, 2015
Life sciences
Germany’s Merck KGaA now considers the world’s emerging markets as a group, with China a major driver, to be a greater revenue-producer than Europe, unit CEO Bernd Reckmann said in an interview.
 
The head of the company’s life science and performance materials unit told China’s Global Times that even as the nation’s economy has become a more normal one, he sees the country providing continued double-digit growth for the company.
 
The emerging markets that include Latin America and all of Asia except Japan provided 38% of the company’s total revenue of $12.5 billion last year, while Europe provided 35%, the company said.
 
Reckmann said China’s slower rate of growth would be more than offset by its increasing healthcare needs and its efforts to encourage more innovation. Merck KGaA, he said, has added to its own investment and manufacturing plants in China, the latest a $104.6 million facility expected to be operational in 2017 to produce drugs on the country’s list of those considered essential.
 
E. Allan Gabor, president and CEO of Merck Serono China, told the Global Times he still considered China a good investment climate, particularly for companies eyeing long-term development.
 
By EJ Lane
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend